Flexion Therapeutics EBIT

Flexion Therapeutics (FLXN) currently reports a EBIT of $-78M as of September 2021. That compares with $-110M in the prior-year period — up 27.5% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Flexion Therapeutics's EBIT history and peer comparisons.

Flexion Therapeutics's EBIT increased from $-110M to $-78M — a 27.5% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Flexion Therapeutics's EBIT of $-78M is lower than the Healthcare sector average of $23B. That is roughly 100.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Flexion Therapeutics reported $-78M in EBIT as of September 2021. That compares with $-110M in the prior-year period — up 27.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-78M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Flexion Therapeutics, and consider following FLXN for alerts when major investors trade the stock.